2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.108 (Poster) Randomized Control Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer

PP01.108 (Poster) Randomized Control Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer

Back to course

Pdf Summary

Mayo Clinic is currently conducting a randomized controlled trial to evaluate the effectiveness of a Shared Decision-Making (SDM) Encounter Tool called 'NSCLC Choice' for adjuvant treatment of lung cancer. Adjuvant therapy, such as chemotherapy or targeted therapy, is known to reduce the recurrence of lung cancer, but the decision to proceed with treatment depends on the patient's values and preferences. The 'NSCLC Choice' tool aims to support patients in making treatment decisions that align with their priorities by providing information on the potential benefits, risks, and inconveniences of available options.<br /><br />The trial is being conducted at Mayo Clinic Rochester and includes both in-person and virtual encounters. Adult patients with stage 1B non-small cell lung cancer (NSCLC) who are eligible for adjuvant treatment are being enrolled. The encounters are video and/or audio recorded with the consent of the clinician and patient.<br /><br />The primary outcome of the trial is to assess the quality of the SDM process, which will be measured using two scales: the self-reported SDMQ-9 questionnaire and the OPTION12 scale. The trial also includes assessments of knowledge transfer, satisfaction, decisional conflict scale, and the treatment decision made by the patient.<br /><br />The trial has a planned sample size of 100 patients and will follow the intention-to-treat principle for the analysis, comparing the outcomes between the 'NSCLC Choice' group and the standard care group at the clinician level. The trial is IRB approved and currently open for enrollment.<br /><br />The 'NSCLC Choice' tool provides information on treatment options, relevant information, initial risk assessment, and the potential benefits of therapy for patients with different characteristics, such as stage 2B or EGFR mutated patients.<br /><br />This trial is funded by a grant from Emerson Collective and has a clinical trials number of NCT06122064.

Asset Subtitle

Mariana Borras Osorio

Keywords

Mayo Clinic

randomized controlled trial

Shared Decision-Making

NSCLC Choice

adjuvant treatment

lung cancer

chemotherapy

patient values

treatment decisions

clinical trials number